Biliary Tract Cancer

New Indication: Trastuzumab plus CISplatin-Gemcitabine in Biliary Tract Cancers

2023-11-20

  • Study

    Investigator-initiated, open-label, single-arm, multi-institutional, phase II trial (TAB)
    Adult patients with HER2-positive, treatment-naïve BTCs
    Trastuzumab + Gemcitabine + Cisplatin (n=90)


  • Efficacy

    ORR: 55.7% [50 of 90 pts]
    mPFS: 7.0 mos [6.2-7.8]
    12 mos PFS: 17.6% [16.7-18.5]
    mOS: 9.96 mos [9.25-10.66]
    12 mos OS: 39.1% [27.3-50.9]

  • Safety

    Grade3: Anemia (29%), neutropenia (20%), aminotransferases elevation (18%), fatigue (17%)


    • Jour of Clin Oncol NOV 09, 2023

    Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB

    http://doi.org/10.1200/JCO.23.01193

    Reviewed by Elvin Chalabiyev, MD on Nov 20, 2023